Two recent landmark randomized controlled trials (Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy (EVEREST II) and Aflibercept in polypoidal choroidal vasculopathy (PLANET)) reported the results of anti-VEGF therapy and PDT in combination for the treatment of PCV. This evidence concerns the gene VEGFA and Polypoidal choroidal vasculopathy.